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Background: By providing estimates of tumor glucose metabolism, 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) can potentially characterize the response of breast tumors to treatment. To assess therapy
response, serial measurements of FDG-PET parameters (derived from static and/or dynamic images) can be
obtained at different time points during the course of treatment. However, most studies track the changes in
average parameter values obtained from the whole tumor, thereby discarding all spatial information manifested in
tumor heterogeneity. Here, we propose a method whereby serially acquired FDG-PET breast data sets can be
spatially co-registered to enable the spatial comparison of parameter maps at the voxel level.
Methods: The goal is to optimally register normal tissues while simultaneously preventing tumor distortion. In
order to accomplish this, we constructed a PET support device to enable PET/CT imaging of the breasts of ten
patients in the prone position and applied a mutual information-based rigid body registration followed by a
non-rigid registration. The non-rigid registration algorithm extended the adaptive bases algorithm (ABA) by
incorporating a tumor volume-preserving constraint, which computed the Jacobian determinant over the tumor
regions as outlined on the PET/CT images, into the cost function. We tested this approach on ten breast cancer
patients undergoing neoadjuvant chemotherapy.
Results: By both qualitative and quantitative evaluation, our constrained algorithm yielded significantly less tumor
distortion than the unconstrained algorithm: considering the tumor volume determined from standard uptake
value maps, the post-registration median tumor volume changes, and the 25th and 75th quantiles were 3.42%
(0%, 13.39%) and 16.93% (9.21%, 49.93%) for the constrained and unconstrained algorithms, respectively (p = 0.002),
while the bending energy (a measure of the smoothness of the deformation) was 0.0015 (0.0005, 0.012) and
0.017 (0.005, 0.044), respectively (p = 0.005).
Conclusion: The results indicate that the constrained ABA algorithm can accurately align prone breast FDG-PET
images acquired at different time points while keeping the tumor from being substantially compressed or distorted.
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18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) can provide estimates of parameters related
to the delivery, retention, and metabolism of glucose, and
therefore has been proposed as a method of characteriz-
ing the response of tumors to treatment [1-4]. To assess
treatment response, semi-quantitative parameters, such
as the standard uptake value (SUV) which is derived from
static images [5,6], or quantitative parameters which are
derived from dynamic images, [7-9], are measured at
different time points during the course of treatment.
Changes in these values on a region of interest (ROI)
basis are then used to assess or predict the response of
tumors to therapy [10,11]. In recent years, there has been
increasing interest in assessing imaging data at the voxel
level, rather than at the ROI level, with the hypothesis
that important information on tumor heterogeneity is
discarded when an ROI average is performed [12,13]. In
order to optimally perform such an analysis during ther-
apy, the data sets acquired at different time points must
be accurately co-registered so that similar sections of tis-
sues can be compared. Towards this end, we have intro-
duced a technique that allows for co-registering breast
MRI data acquired at different imaging sessions during
therapy [14,15]. In this effort, we seek to amend this
method to perform longitudinal registration of PET/CT
data of the breast in order to enable voxel level analysis
of changes observed in FDG-PET images acquired during
therapy.
The motivation for developing a method for character-
izing changes in FDG-PET scans at the voxel level comes
from the fact that probing tumor heterogeneity, as well
as changes in that heterogeneity over time, is gaining
prominence as a research topic [16]. As MRI studies have
shown changes in heterogeneity are predictive of response
[13], it is natural to apply a similar approach in studying
FDG-PET data. Indeed, as FDG-PET is becoming more
accepted in assessing changes in tumor metabolism over
time (see, e.g., the most recent version of the Response
Evaluation Criteria in Solid Tumors, RECIST [17,18]),
the ability to compare the same section of tissue will be-
come increasingly important. While the limited spatial
resolution of PET (compared to, e.g., MRI and CT) is a
potential barrier for performing such a comparison, it
certainly must be addressed to determine if such a prom-
ising approach is viable. As has been noted recently [19],
volumes of interest established just prior to the initiation
of therapy (i.e., baseline images) are not easily trans-
formed to images acquired at later time points, thereby
making attempts to study changes in heterogeneity
challenging. In this effort, we present one approach to
potentially mitigate such difficulties.
There are three main challenges in performing
longitudinal registration of breast FDG-PET images:(1) differences in patient positioning between consecutive
imaging sessions, (2) changes in tumor shape and volume
between imaging sessions, and (3) the relatively low
spatial resolution of PET images. To minimize the error
introduced by differences in patient positioning, we have
designed a support device that allows for PET imaging
in the prone position. This allows for the breasts to lay
pendant during the scanning session, rather than flat
against the chest as in the supine position. It is important
to note that we are not the first to introduce this tech-
nique; Moy et al. [20] have used prone PET imaging of
the breast to facilitate registration of PET data to MRI
data, where it has been applied to assist in diagnosis
[21,22]. The second problem, addressing the changes in
tumor shape and volume that occur due to therapy,
requires a registration technique that can maximally
align the breast volumes while minimally distorting the
tumor, the volume of which must be kept true to what is
measured at each time point [14,15]. That is, if V(t1) is
the tumor volume at time t1 (e.g., pre-treatment), and
VR(t1) is the tumor volume after registration to the post-
treatment image, then the registration scheme should
minimize the differences between V(t1) and VR(t1). Similar
comments apply for time t2. To achieve this, we developed
and applied a spatially constrained, non-rigid registration
method previously used for longitudinal registration of MR
images, which incorporates a tumor volume-preserving
constraint. The third problem is addressed by applying
the algorithm on the computed tomography (CT) images
that are acquired during the PET/CT acquisition and
applying the resulting transformation to the PET data. We
tested our approach on ten patients receiving neoadjuvant
chemotherapy for breast cancer, who were scanned at
three different time points: pre-therapy, after one cycle of
therapy, and at the conclusion of therapy. The PET/CT
data at the first two time points were co-registered to the
data at the third time point by applying constrained and
unconstrained registration algorithms. Both qualitative
visual comparisons, as well as a quantitative analysis of
the change in the median tumor volume determined
from the SUV maps and bending energy obtained from
the deformation fields (DF), were employed to evaluate
the performance of the registration algorithms.
Methods
Patient population
Data were acquired from ten patients with locally
advanced breast cancer, who were enrolled in an on-
going phase II clinical trial that is investigating whether
the addition of an mTOR inhibitor (RAD001) would
have synergistic effects with cisplatin in triple negative
breast cancer. The patients provided informed consent,
and the study was approved by our Institutional Review
Board. Patients with measurable clinical stage II/III
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25 mg/m2 with and without RAD001 30 mg weekly for
3 weeks, followed by cisplatin + paclitaxel 80 mg/m2 with
and without RAD001 weekly for 9 weeks until the time
of definitive surgery. FDG-PET/CT images of the patients
were obtained before (t1), after one cycle (t2), and at the
completion of neoadjuvant chemotherapy (t3), yielding a
total of 30 data sets (ten patients × three time points).
For each patient, we registered the data from t1 to t3 and
the data from t2 to t3, thereby yielding 20 data sets in
which to test the registration algorithms.
Data acquisition
Figure 1 displays the specially designed device to enable
PET imaging of the breast in the prone position. It is an
exact geometric replica of the 4-channel receiver double-
breast radiofrequency coil (In vivo Inc., Gainesville, FL,
USA) used on our Philips 3T Achieva MR scanner (Philips
Healthcare, Best, The Netherlands). A separate, ongoing
study is examining the ability to facilitate co-registration
of FDG-PET data with MRI data. The rigidity of the
device is provided by lightweight, rigid polystyrene foam
insulation (part # 9255K3; McMaster, Atlanta, GA, USA),
which was purchased in bulk and machined to match the
dimensions of the breast coil. To provide patient com-
fort, a set of the padding used to support patients for the
MRI coil was purchased and affixed to the support (please
see Figure 1). Once constructed, the support device was
assessed for CT attenuation by certified PET/CT technol-
ogists. For a similar approach and design, please see the
work by Moy et al. [20-22].
PET/CT data were acquired with a GE Discovery
STE scanner (GE Healthcare, Waukesha, WI, USA). A
low-mAs CT scan was acquired for attenuation correc-
tion of the emission data. The acquisition parameters forFigure 1 Our own support for prone breast PET/CT images. It allows fo
greatly enhancing the ability to perform longitudinal registration. Typical b
reproducible patient positioning between scan sessions.the transmission CT scan were the following: the tube
current was 80 mAs for a 70-kg patient and scaled ac-
cordingly for all patients, the tube voltage was 120 KVp,
and the pitch was 1.675/1. The activity of FDG adminis-
tered was approximately 370 MBq (10 mCi) for a 70-kg
patient and scaled according to weight. FDG was admi-
nistered intravenously via an antecubital vein contra-
lateral to the affected breast. After 60 min, emission data
was collected in 3D mode for 2 min per bed position.
The emission scan was first collected in the prone position
over the breast only, and then in the supine position from
the skull to mid-femurs. Standard-of-care supine images
and research prone images were acquired at times t1 and
t3, while only the prone images were acquired at t2.
Image registration methods
While details of our constrained, non-rigid registration
algorithm for alignment of breast images acquired during
therapy technique can be found elsewhere [14,15], we
briefly describe the salient features and enhancements
required to apply the approach to PET/CT data. A rigid
body registration algorithm [23] is first used to align the
breast CT images at t1 and t2 to the target images at t3.
This algorithm searches the optimal rotation and trans-
lation parameters through maximizing the normalized
mutual information (NMI, Equation 1):
NMI ¼ H Að Þ þ H Bð Þ
H A;Bð Þ ; ð1Þ
where H(A) and H(B) are the marginal entropy of images
A and B, and H(A,B) is the joint entropy. A non-rigid
registration method [14] is then applied to the longitu-
dinal breast CT images between the first two time points
and the third. This method relies on the adaptive basesr the breasts to lie pendant during the scanning procedure, therefore
reast PET/CT is performed in the supine position which results in less
Li et al. EJNMMI Research 2012, 2:62 Page 4 of 11
http://www.ejnmmires.com/content/2/1/62algorithm (ABA) [24]. The ABA algorithm employs NMI
as the similarity measure, and the deformation field is
modeled by a linear combination of radial basis functions
[25]. Through searching the optimal coefficients of radial
basis functions, the NMI can be maximized, and the
deformation field that registers the two images can be
obtained. The ABA algorithm is applied using a hier-
archical multi-resolution strategy, in which the original
PET/CT images are down-sampled into a number of
low-resolution images, and the registration starts at a
low resolution level, with few basis functions, and ends
at the highest resolution level.
For the present application, we extend the ABA algo-
rithm by incorporating an additional term (i.e., the con-
straint) designed to preserve the tumor volume during
the registration process in the cost function. This term is
computed as the Jacobian determinant over the tumor
regions as outlined on the PET/CT (described below)
images; hence, the cost function is composed of two
terms: the negative NMI term and the tumor volume
constraint term:
f cost ¼ NMI þ α
Z
T
log JT xð Þð Þj jdx; ð2Þ
where JT(x) is the Jacobian determinant on the tumor
area, and α is the parameter to control the weight of this
constraint term. The value of α can be adjusted from 0
to 1 based on individual datasets; the smaller the weight,
the less the tumor volume is constrained (please see the
‘Discussion’ section for more comments on this technical
point). For the patient data sets in this study, a weight of
0.1 was unable to constrain the tumor volume for some
patients, while a weight of 0.5 was too strong to allow the
reorientation of the tumor in other patients; thus, a weight
of 0.3 was (empirically) selected for all 20 pairs of image
sets. Through minimizing the cost function, the algorithm
optimally registers the normal tissues while simultan-
eously minimizing tumor distortion.
To perform the constrained registration, the tumor
volume must first be segmented. We note that determin-
ation of the tumor volume in PET images by thresholding
is still an area of active discussion. For example, Drever
et al. [26] have shown that the optimal threshold depends
mainly on lesion size and contrast, and that a threshold
of 40% can be reasonable for larger lesions. However,
Biehl et al. [27] showed that the PET and CT gross tumor
volumes were approximately equal using a threshold of
40% for tumors less than 3 cm. As an in-depth analysis of
the determination of the threshold was outside the scope
of the study, we simply segmented the tumor volume
using a threshold of 40% of the maximum SUV uptake, a
common method to delineate tumor volumes on SUV
maps of FDG [28-30]. More specifically, the SUV mapswere calculated for each patient and loaded into in-house
software (based on MATLAB, Natick, MA, USA). An
experienced radiologist drew tumor ROIs large enough
to ensure that all possible tumor voxels were included.
These manually drawn ROIs may also include some
healthy tissue voxels. The ROIs for each slice were then
combined to generate 3D masks. The final tumor volume
is detected by finding all voxels with SUV larger than
40% of the maximum SUV uptake in the 3D masks.
These are the tumor voxels, the Jacobian determinant of
which is minimized during the application of the con-
strained algorithm in order to maximally preserve the
tumor volume during the registration process. It is also
important to note that our previous studies [15] have
shown that the selection of the tumor volume (i.e., the
volume of tissue that is to be constrained during the
registration process) does not significantly affect the per-
formance of the method.
Figure 2 shows the scheme for applying the algorithm
to register the PET/CT images acquired at the three time
points throughout therapy. The CT data at t1 and t2 were
registered to the CT data at t3 (though, in principle, any
time point could be selected as the ‘target’ to which the
other time points are aligned), yielding the deformation
fields (steps A and B in the figure). The deformation
fields were then applied to the corresponding PET images
obtained at t1 and t2 (steps C and D), respectively, so that
all data are aligned to the t3 images at the end of the
process.
Validation approach
The validity of the constrained and unconstrained algo-
rithms was tested both qualitatively and quantitatively.
Qualitative assessment involved visual comparisons of
the PET/CT images and deformation fields before and
after registration using the constrained and unconstrained
algorithms. Quantitative assessment was performed by
calculating (1) the changes in the SUV tumor volumes
after registration and (2) the bending energy. The bending
energy, which describes the smoothness of the deform-
ation fields [15], is calculated as follows:
Ebending ¼ 1V ∭ ∂
2T=∂x2
 2 þ ∂2T=∂y2 2
þ ∂2T=∂z2 2 þ 2 ∂2T=∂x∂y 2
þ 2 ∂2T=∂x∂z 2 þ 2 ∂2T=∂y∂z 2dxdydz;
ð3Þ
where T is the transformation, and V is the tumor volume.
The percentage change of tumor volumes is used to
measure the degree the constrained algorithm preserves
tumor volume or the extent the unconstrained algorithm
distorts the tumor. When looking at the longitudinal
Figure 2 The scheme for applying the algorithm to register the PET/CT. The CT data obtained during t1 and t2 are aligned via the proposed
registration algorithm (steps A and B) to the CT images acquired at t3. The resulting DF are then applied to the corresponding PET images to
yield co-registered longitudinal PET data (steps C and D).
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is to predict which patient will achieve a positive re-
sponse. Any change in tumor size should be due to
changes in biology and not to changes in patient posi-
tioning or errors in the registration scheme. Thus, we
want to make sure that changes in the tumor volume
are absolutely minimized during registration. Given our
earlier result on applying this technique to MRI data, we
hypothesized that the tumor volume will be similar
before and after applying the constrained ABA regis-
tration algorithm (i.e., Equation 2), while the tumor
volume will be changed substantially using the uncon-
strained ABA registration algorithm (i.e., Equation 2
without the second term on the right hand side) because
the unconstrained algorithm tends to compress or
stretch the tumor at early stages of treatment (i.e., t1
and t2) to match the post-treatment (i.e., t3) tumor size
and shape. We also hypothesized that compared with
the unconstrained ABA approach, the constrained ABA
algorithm will lead to a smoother transformation, and
therefore a smaller bending energy.Statistical analysis
We used the Lilliefors test to determine if the change
of the tumor volumes and the bending energy came
from a normal distribution. The test showed that the
data did not come from a normal family (p < 0.05 for
the bending energy obtained by both the constrained
and unconstrained algorithms and the tumor volume
change obtained by the unconstrained algorithm).
Hence, instead of using the mean and standard deviation,
the median and the lower and upper quantiles (the 25th
and 75th quantiles) were reported for the change of the
tumor volumes and the bending energy. The non-
parametric Wilcoxon signed rank test was then applied
to determine if the results obtained by the constrained
and unconstrained ABA algorithms were significantly
different.
Results
Qualitative assessment of registration algorithms
In general, the rigid body registration algorithm provided
imperfect alignment of breast tissue. The unconstrained
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at the expense of dramatically shrinking the tumor to
match the tumor shape, whereas the constrained ABA
achieved a (qualitatively) satisfactory alignment in the
normal tissues with only minimal distortion of the tumor.
Figures 3 and 4 display representative registration results
for two patients who were each diagnosed with an inva-
sive ductal carcinoma. In each panel, the standardized
uptake values are superimposed on the anatomical CT
images. The first column of each figure shows three
axial slices obtained by aligning the PET/CT images at
t1 (row 1) and t2 (row 2) to the PET/CT data acquired
at t3 (row 3) via a rigid body registration. The second
and third columns show the same slices registered by the
unconstrained and constrained ABA algorithms, respect-
ively. The contours of the CT images at t3 were drawn
and then copied to other images to facilitate the com-
parison. In the fourth row, the first panel displays theFigure 3 A representative patient displaying the results of the three r
time points, and the three columns show the results after rigid body regist
constrained ABA registration (ABA_CON), respectively. In the fourth row, th
when the images at t1 are registered to the images at t3, while the second
panels display similar data when the images at t2 are registered to the ima
contour of the CT image at t3 is drawn and then copied to other images tdeformation field generated by the unconstrained algo-
rithm when the images at t1 were registered to the images
at t3, while the second panel shows the result using the
constrained algorithm; the third and fourth panels display
similar data when the images at t2 were registered to the
images at t3, respectively. The first column (left-most)
shows that the rigid body registration provided a general
alignment of breast tissues imaged at the three time points
but was not perfect. Column 2 shows that the uncon-
strained registration provides an accurate registration of
the breast tissues, but only at the expense of dramatic-
ally shrinking the tumor observed at times t1 and t2 to
match the tumor shape at t3. The constrained algorithm
(column 3) achieved a high degree of accuracy in the
normal tissues with only minimal distortion of the
tumor. Figure 4 displays similar panels, and the results
also indicate that the constrained algorithm protects the
tumor from large distortion. Column 3 in Figure 4 alsoegistration algorithms. The first three rows correspond to the three
ration, after unconstrained ABA registration (ABA), and with
e first panel displays the deformation field generated by the ABA
panel shows the result using the ABA_CON; the third and fourth
ges at t3, respectively. The green circle shows the tumor location. The
o facilitate the comparison.
Figure 4 Results of the three registration algorithms for another patient with similar setup with Figure 3.
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breast, since the tumor is large and the constrained term
dominates the registration algorithm over the tumor
area, leading to the preservation of the tumor volume
but to the small mismatch of surrounding tissues. Also
note that even though there is no visible tumor in the
PET image at t3, the constrained algorithm still success-
fully preserves the overall volume and shape of the tumor
at t1 and t2.
Figure 5 shows ten example images from the ten
patients in which the CT images obtained at t1 or t2
(colored in blue) are overlaid on the images at t3 (gray)
in a checkerboard pattern to facilitate assessments of the
registration performance. Note that the structural bound-
aries between blue and gray images are connected accur-
ately, indicating the accuracy of the registration algorithm.
Quantitative assessment of registration algorithms
Returning to Figure 3 (also refer to patient #1 in Table 1),
the changes in tumor volume from t1 to t3 and from t2
to t3 obtained by the constrained ABA algorithm are0.0% and 7.59%, respectively, while application of the
unconstrained ABA algorithm results in tumor volume
changes of 63.21% and 78.99%, respectively. The bending
energies are 0.002 and 0.0, respectively, for the con-
strained algorithm, while the unconstrained algorithm
results in the bending energies of 0.052 and 0.036, re-
spectively. Similarly, for Figure 4 (also refer to patient #2
in Table 1), the changes in tumor volume from t1 to t3
and from t2 to t3 obtained by the constrained ABA algo-
rithm are 9.28% and 0.09%, and the bending energies are
0.0 and 0.001, respectively, while the unconstrained algo-
rithm results in tumor volume changes of 63.13% and
61.07%, respectively, and the bending energies of 0.079
and 0.051, respectively. Table 1 lists the bending energies
and volume changes for ten patients. For each patient,
the data at t1 was registered to t3, and the data at t2 was
registered to t3, yielding a total of 20 datasets. The
median and lower and upper quantiles of tumor volume
changes are 3.42% (0%, 13.39%) and 16.93% (9.21%,
49.93%) (p = 0.002) for the constrained and unconstrained
ABA algorithm, respectively, while the median bending
Figure 5 Ten examples from ten patients illustrating the matching accuracy of the registration algorithm. Axial CT slices obtained at t1
or t2 (colored in blue) are overlaid on the corresponding images obtained at t3 (gray) in a checkerboard pattern to facilitate assessments of the
registration performance. Note that the structural boundaries between blue and gray images are connected accurately, indicating a good
performance of the registration algorithm.
Li et al. EJNMMI Research 2012, 2:62 Page 8 of 11
http://www.ejnmmires.com/content/2/1/62energy is 0.0015 (0.0005, 0.012) and 0.017 (0.005, 0.044),
respectively (p = 0.005). The results indicate that the
constrained approach is significantly better than the un-
constrained approach in preserving the tumor volume
during longitudinal registration.Table 1 The bending energy and change of tumor volumes a
unconstrained ABA algorithms (ABA), respectively
Patient number Dataset Bending e
ABA
1 t1→ t3 0.052
t2→ t3 0.036
2 t1→ t3 0.079
t2→ t3 0.051
3 t1→ t3 0.021
t2→ t3 0.036
4 t1→ t3 0.057
t2→ t3 0.004
5 t1→ t3 0.011
t2→ t3 0.012
6 t1→ t3 0.051
t2→ t3 0.020
7 t1→ t3 0.019
t2→ t3 0.006
8 t1→ t3 0.015
t2→ t3 0.012
9 t1→ t3 0.004
t2→ t3 0.001
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obtained for MR images were 4.8% and 46.9% for the con-
strained and unconstrained algorithms, respectively, and
the bending energies were 0.0058 and 0.15, respectively
[15]. The accurate performance of this algorithm on MR
data makes it a promising technique to apply on longi-
tudinally acquired breast data available from other
modalities. In this effort, we have applied the con-
strained, non-rigid registration algorithm to sequential
breast PET/CT images acquired during neoadjuvant
chemotherapy. Visual assessment (Figures 3, 4, and 5)
demonstrates that the algorithm leads to accurate registra-
tion results. Quantitative assessment (Table 1) also shows
that the algorithm yields smoother deformation fields
and significantly less tumor volume change compared
with the unconstrained, non-rigid registration algorithm.
One limitation of this study is that the registration
algorithm may not correct the change in the whole breast
volume over time, e.g., due to hormonal fluctuations over
the menstrual cycle [31]. In the current technique, the
constrained term is applied to the tumor ROI to preserve
the tumor volumes, and NMI is used to perform the
alignment. Therefore, this technique may not be able to
handle changes in overall breast volume.
We note that there are some negative volume changes
in Table 1. This may have occurred since the difference
of patient positioning in particular cases could be large,
resulting in large deformation during registration between
two time points. Under some circumstances, the registra-
tion algorithm must stretch the healthy tissue in the
source image to match with the target image. When the
mutual information term in the cost function is sub-
stantially greater than the constraint term, both the
healthy tissue and the tumor area will be stretched during
registration, and this could result in tumor expansion.
We also note that for some patients (e.g., patients #5
and 7 in Table 1), the results obtained by both the
constrained and unconstrained algorithms were very
similar. One possible reason is that for all 20 data sets,
we use similar registration parameter settings (e.g., the
number of radial basis functions and the total resolution
levels); in particular, we fixed the weight of the constraint
term, α, to a value of 0.3. However, as the tumor shape,
volume, and normal tissue structures are substantially
different between patients, it is highly likely that empir-
ical adjustment of those parameters for different patients
would improve the performance of the constrained. One
of the future goals is to automate the optimal selection
of these parameters. Another future direction is to use
MR images to further verify the performance of the
constrained algorithm on PET/CT images. As mentioned
above, MR images have a higher spatial resolution (than
PET) and could be used to examine if larger voxel size
or partial volume effect causes the registration inaccuracyin PET/CT data, though applying the transformation
obtained from PET/CT data to MR images.
Although currently, most studies still focus on the
assessment of physiological parameters at the ROI level,
investigators have realized the importance of tumor het-
erogeneity contained in parametric maps. Maday et al.
[12] employed a deformable registration and texture ana-
lysis on breast magnetic resonance images to assess the
response of breast cancer to therapy and concluded that
their approach improved the ability to predict response.
Padhani et al. [13] also reported that the change in the
range of tumor perfusion and permeability estimated
by MRI was able to predict breast cancer response to
treatment, indicating that intra-tumoral heterogeneity
is important. O'Connor et al. [32] also showed that
DCE-MRI biomarkers of tumor heterogeneity may pre-
dict the shrinkage of colorectal cancer liver metastasis.
Li et al. [33] applied longitudinal registration to DCE-
MRI data and performed a voxel-by-voxel analysis. Their
preliminary results indicated that the voxel-based ana-
lysis may improve the ability of DCE-MRI parameters
to separate complete responders from non-responders
after one cycle of chemotherapy. Hence, longitudinal
registration keeps the information of tumor heterogeneity
and spatial distribution of the physiological parameters,
thereby enabling spatial comparison at the voxel level. It is
a reasonable hypothesis that registration of PET/CT breast
images obtained during therapy may allow for an improve-
ment in assessing and/or predicting treatment response.
Hence, future efforts will apply the algorithm to para-
metric maps (e.g., the standard uptake value) to investigate
if assessing the changes at the voxel level can improve,
over region-of-interest-based measurements, the ability
of FDG-PET to predict the response of breast tumors to
neoadjuvant chemotherapy. In particular, it will be import-
ant to determine if the constrained algorithm can limit
registration errors to such a level that they would be
acceptable for clinical evaluation based on voxel (or, at
least, local) uptake analysis. As our data set grows, this
will be a primary goal to address. Such an analysis has
been applied in MRI longitudinal studies of treatment
response in cancer [33-35], and the methods presented in
this contribution enable such an approach for PET data.Conclusion
This study indicates that the constrained registration
method can accurately align prone breast FDG-PET
images acquired at different time points while keeping
the tumor from being substantially compressed or dis-
torted. Future studies, in a larger cohort of patients, will
test whether the approach can enhance the ability to pre-
dict eventual response, thereby by providing an import-
ant (clinical) validation.
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